SCHEMBL4933166

SCHEMBL4933166

CCOc1ccc(-n2c(=O)[nH]c3ccc(Cl)cc32)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
LMNA P02545 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
MAOB P27338 3/20 0.47
DAO P14920 1/20 0.47
ALDH1A1 P00352 2/20 0.46
TSHR P16473 1/20 0.46
HTT P42858 1/20 0.46
AURKA O14965 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
MAPT P10636 3/20 0.44
ESR2 Q92731 1/20 0.43
HSD17B10 Q99714 1/20 0.43
GABRP O00591 1/20 0.42
GABRD O14764 1/20 0.42
GABRA1 P14867 1/20 0.42
GABRB1 P18505 1/20 0.42
GABRG2 P18507 1/20 0.42
GABRB3 P28472 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4928761 0.90 L3MBTL1 (0.47) MEN1KMT2ALMNAL3MBTL1MAOB
SCHEMBL4931086 0.90 L3MBTL1 (0.47) MEN1KMT2ALMNAL3MBTL1MAOB
SCHEMBL4929992 0.90 KMT2A (0.63) MEN1KMT2ALMNAL3MBTL1MAOB
SCHEMBL4928439 0.86 MEN1 (0.50) MEN1KMT2ALMNAL3MBTL1MAOB
SCHEMBL4931135 0.85 GABRP (0.56) MEN1KMT2ALMNAL3MBTL1MAOB
SCHEMBL4928742 0.85 PSMB8 (0.50) MEN1KMT2AALDH1A1TSHRSMN1; SMN2
SCHEMBL4933359 0.84 MEN1 (0.46) MEN1KMT2ALMNAL3MBTL1MAOB
SCHEMBL11348908 0.83 LMNA (0.62) MEN1KMT2ALMNAL3MBTL1DAO
SCHEMBL8886041 0.83 ATM (0.50) MEN1KMT2AMAOBALDH1A1TSHR
SCHEMBL8884813 0.82 MAOB (0.61) MEN1KMT2AMAOBALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
EP-1810677-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2007-07-25 EP disclosed
EP-1810677-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2007-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021069-A1 Receptor Function Regulating Agent GPR119, INSR, GPR65 MEN1 4097/4885KMT2A 1963/4885LMNA 4744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.